clinical trial · NCT05673057
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
LeukemiaMyeloidAcuteNewly DiagnosedMP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm AMP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclaxMP0533 with Obinutuzumab pretreatmentMP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AMLMP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients
brief summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
started
Dec 29, 2022
primary completion
May 29, 2026
completion
May 1, 2027
last updated
Jun 9, 2026
official title
A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol